Table 1:
|
Severity |
|||||||||
|
Related Factors |
Mild N = 60 (33.0%) |
Moderate N = 82 (45.1%) |
Severe N = 40 (22.0%) |
χ 2 |
F-test |
φ |
|||
|
BIOCHEMICAL MARKERS |
|||||||||
|
TBARS [Normal] |
18 (30.0%) |
0 (0.0%) |
0 (0.0%) |
76.34* |
63.44 |
0.458 |
|||
|
TBARS [High] |
0 (0.0%) |
0 (0.0%) |
10 (25.0%) |
|
|
|
|||
|
TBARS [Elevated] |
42 (70.0%) |
82(100.0%) |
30 (75.0%) |
|
|
|
|||
|
CLINICAL COMPLICATIONS |
|||||||||
|
Stroke [Yes] |
21 (35.0%) |
82(100.0%) |
40 (100.0%) |
100.92* |
103.53 |
0.745 |
|||
|
Stroke [No] |
39 (65.0%) |
0 (0.0%) |
0 (0.0%) |
|
|
|
|||
|
Pain Crises [0-2] |
15 (25.0%) |
82 (100.0%) |
22 (55.0%) |
186.0* |
173.04 |
0.715 |
|||
|
Pain Crises [3-5] |
45 (75.0%) |
0 (0.0%) |
0 (0.0%) |
|
|
|
|||
|
Pain Crises [ ≥ 6] |
0 (0.0%) |
0 (0.0%) |
18 (45.0%) |
|
|
|
|||
|
Number of Infections [0-2] |
40 (66.7%) |
82 (100.0%) |
40 (100.0%) |
45.6 |
43.36 |
0.501 |
|||
|
Number of Infections [3-5] |
20 (33.3%) |
0 (0.0%) |
0 (0.0%) |
|
|
|
|||
|
Number of Infections [ ≥ 6] |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
|
|
|
|||
|
HEMATOLOGICAL MARKERS |
|||||||||
|
Ferritin [Low] |
0 (0.0%) |
4 (4.9%) |
0 (0.0%) |
272.3* |
258.37 |
0.865 |
|||
|
Ferritin [Normal] |
60 (100.0%) |
18 (22.0%) |
0 (0.0%) |
|
|
|
|||
|
Ferritin [High] |
0 (0.0%) |
3 (3.7%) |
40 (100.0%) |
|
|
|
|||
|
Ferritin [Elevated] |
0 (0.0%) |
57 (69.5%) |
0 (0.0%) |
|
|
|
|||
|
MOLECULAR MARKERS |
|||||||||
|
TNF-α [AA] |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
134.31* |
118.17 |
0.857 |
|||
|
TNF-α [GA] |
0 (0.0%) |
0 (0.0%) |
31 (75.6%) |
|
|
|
|||
|
|
TNF-α [GG] |
60 (100.0%) |
2 (100.0%) |
9 (22.0%) |
|
|
|
||
|
|
TGF-β [CC] |
0 (0.0%) |
60 (73.2 %) |
40 (100.0%) |
124.4* |
166.51 |
0.585 |
||
|
|
TGF-β [CT] |
44 (73.3%) |
22 (26.8%) |
0 (0.0%) |
|
|
|
||
|
|
TGF-β [TT] |
16 (26.8%) |
0 (0.0%) |
0 (0.0%) |
|
|
|
||
|
|
eNOS [CC] |
0 (0.0%) |
0 (0.0%) |
5 (12.5%) |
107.1* |
129.1 |
0.543 |
||
|
|
eNOS [CT] |
0 (0.0%) |
34 (41.5%) |
35 (87.5%) |
|
|
|
||
|
|
eNOS [TT] |
60 (100.0%) |
48 (58.5%) |
0 (0.0%) |
|
|
|
||
|
|
H63D [H63D/H63D] |
0 (0.0%) |
0 (0.0%) |
2 (4.9%) |
114.87* |
142.0 |
0.560 |
||
|
|
H63D [W/H63D] |
0 (0.0%) |
55 (67.1%) |
39 (97.5%) |
|
|
|
||
|
|
H63D [W/W] |
60(100.0%) |
27 (32.9%) |
0 (0.0%) |
|
|
|
||
|
|
C282Y [W/C282Y] |
0 (0.0%) |
0 (0.0%) |
3 (9.8%) |
14.63* |
9.21 |
0.278 |
||
|
|
C282Y [W/W] |
60 (100.0%) |
82 (100.0%) |
37 (92.5%) |
|
|
|
||
|
|
S65C [W/S65C] |
0 (0.0%) |
0 (0.0%) |
1 (2.5%) |
3.57* |
2.79 |
0.140 |
||
|
|
S65C [W/W] |
60 (100.0%) |
82 (100.0%) |
39 (97.5%) |
|
|
|
||
*Statistically significant p < 0.05, df = 4; n = 182 patients; φ ∈ [0.1, 0.3]: Weak association; φ ∈ [0.4, 0.5]: Medium association; φ > 0.5: strong association; n = 182 patient is.